| Home | E-Submission | Sitemap | Contact Us |  
logo
The Korean Journal of Medicine 2007;73(5): 464-473.
원저 : 인터페론 용량에 따른 만성 B형 간염 치료에 대한 유효성 평가
김태호&#;김창환&#;조근종&#;한석원&#;정대영&#;김진일&#;최규용, Chang-Whan Kim, Keun Jong Cho, Sok-Won Han, Dae Young Cheong, Jin Il Kim, Kyu Yong Choi
A comparative study on the efficacy of different dosage of alpha-interferon treatment in patients with chronic hepatitis B
Tae Ho Kim, Chang-Whan Kim, Keun Jong Cho, Sok-Won Han, Dae Young Cheong, Jin Il Kim, Kyu Yong Choi
경희대학교 의과대학 순환기내과학교실
ABSTRACT
Background : Infection with hepatitis B virus has been a major health problem. Chronic viral hepatitis B is the principal cause of chronic liver disease, cirrhosis, and hepatoma. A number of studies have showed that a course of interferon (INF) treatment induces a long-term remission in 20~40% of patients. Compared with the use of lamivudine, INF therapy is followed by delayed clearance of HBsAg and the treatment improves the natural history of chronic hepatitis B. The aim of this study is to evaluate the efficacy of the use of different dosages of alpha-interferon treatment in patients with chronic hepatitis B. Methods : We conducted a one-and-a-half year, randomized clinical trial of interferon in 24 Korean chronic hepatitis B patients with a positive HBeAg, and excluded other liver problems with biopsies. The patients were randomly assigned to receive 5 million units (n=10) of interferon-α2b and 10 million units (n=14) of interferon-α2b three times weekly for 16/24 weeks. Patients were followed for 12 months after the cessation of the therapy, and the patients received a second biopsy. Results : After treatment with interferon, 29.2% of the patients became negative for HBeAg and the presence of HBV DNA. Fifty percent of the patients showed histological improvement. The differences of the loss of HBeAg, HBV DNA and histological improvement between the two groups were not significant. HBV DNA and ALT were not valuable as predictive variables in treatment efficacy. However, the rate of histological improvement in patients with a low ALT level was higher. Conclusions : The administration of different doses of interferon-α2b during treatment in patients with chronic hepatitis B did not show a significant difference in efficacy.(Korean J Med 73:464-473, 2007)
Keywords: Hepatitis B, chronic, Interferon alfa
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community